Trial Profile
An Open-Label Phase 1b Clinical Study of Intravenous CAVATAK (Coxsackievirus A21, CVA21), in Combination With Ipilimumab in Subjects With Uveal Melanoma Metastatic to Liver (VLA-024 CLEVER)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Jun 2019
Price :
$35
*
At a glance
- Drugs Gebasaxturev (Primary) ; Ipilimumab
- Indications Uveal melanoma
- Focus Adverse reactions
- Acronyms CLEVER
- Sponsors Viralytics
- 19 Jun 2019 Status changed from active, no longer recruiting to completed.
- 04 Apr 2019 Planned End Date changed from 15 May 2020 to 14 Jan 2020.
- 04 Apr 2019 Planned primary completion date changed from 15 Dec 2019 to 14 Jan 2020.